Morgan Stanley’s Aligos Therapeutics ALGS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $28.9K | Sell |
4,005
-3,493
| -47% | -$25.2K | ﹤0.01% | 6523 |
|
|
2025
Q1 | $61.9K | Buy |
7,498
+4,265
| +132% | +$35.2K | ﹤0.01% | 6198 |
|
|
2024
Q4 | $129K | Buy |
3,233
+3,099
| +2,313% | +$123K | ﹤0.01% | 5960 |
|
|
2024
Q3 | $1.16K | Buy |
134
+2
| +2% | +$17 | ﹤0.01% | 7206 |
|
|
2024
Q2 | $1.16K | Hold |
132
| – | – | ﹤0.01% | 7138 |
|
|
2024
Q1 | $3.23K | Sell |
132
-28
| -18% | -$686 | ﹤0.01% | 6987 |
|
|
2023
Q4 | $2.66K | Buy |
160
+80
| +100% | +$1.33K | ﹤0.01% | 7101 |
|
|
2023
Q3 | $1.49K | Sell |
80
-40
| -33% | -$747 | ﹤0.01% | 7175 |
|
|
2023
Q2 | $2.91K | Sell |
120
-5,189
| -98% | -$126K | ﹤0.01% | 7114 |
|
|
2023
Q1 | $116K | Buy |
5,309
+5,215
| +5,548% | +$114K | ﹤0.01% | 5951 |
|
|
2022
Q4 | $2.24K | Sell |
94
-317
| -77% | -$7.56K | ﹤0.01% | 7342 |
|
|
2022
Q3 | $11K | Sell |
411
-1,694
| -80% | -$45.3K | ﹤0.01% | 7033 |
|
|
2022
Q2 | $64K | Sell |
2,105
-1,099
| -34% | -$33.4K | ﹤0.01% | 6494 |
|
|
2022
Q1 | $171K | Buy |
3,204
+1,137
| +55% | +$60.7K | ﹤0.01% | 6005 |
|
|
2021
Q4 | $613K | Sell |
2,067
-16,709
| -89% | -$4.96M | ﹤0.01% | 5417 |
|
|
2021
Q3 | $7.28M | Buy |
18,776
+18,142
| +2,862% | +$7.03M | ﹤0.01% | 3288 |
|
|
2021
Q2 | $324K | Sell |
634
-739
| -54% | -$378K | ﹤0.01% | 5763 |
|
|
2021
Q1 | $780K | Buy |
1,373
+549
| +67% | +$312K | ﹤0.01% | 4885 |
|
|
2020
Q4 | $570K | Buy |
+824
| New | +$570K | ﹤0.01% | 4998 |
|